Study of ORGN001 (Formerly ALXN1101) in Neonates, Infants and Children With Molybdenum Cofactor Deficiency (MOCD) Type A
Completed · Phase 2/Phase 3
Conditions studied: Molybdenum Cofactor Deficiency, Type A
In brief
To evaluate the safety and efficacy of ORGN001(formerly ALXN1101) in neonate patients with MoCD Type A
Key facts
- Study ID
- NCT02629393
- Run by
- Origin Biosciences
- People needed
- 5
- Starts
- 2016-05-01
- Expected to finish
- 2022-10-01
- Last updated by the study team
- 2023-10-17
Who can join
Age: 0 and older, up to 5. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Children's Hosptial of Michigan — Detroit, Michigan, United States
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States
- Children's Hospital of Wisconsin — Milwaukee, Wisconsin, United States
- HaEmek Medical Center — Afula, Israel
- Stavanger Universitetssjukehus — Stavanger, Norway
- Hospital Sant Joan de Deu — Esplugues de Llobregat, Barcelona, Spain
- Hacettepe University of Medicine — Ankara, Turkey (Türkiye)
- Gazi University — Ankara, Turkey (Türkiye)
- Akdeniz University Medical Faculty — Antalya, Turkey (Türkiye)
- Willink Biochemical Genetics Unit — Manchester, Greater Manchester, United Kingdom
- Great Ormond Street Hosptial — London, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.